-+ 0.00%
-+ 0.00%
-+ 0.00%

REGENERON PHARMACEUTICALS - IPR&D CHARGE EXPECTED TO REDUCE Q3 2026 GAAP AND NON-GAAP EPS BY $0.18 - SEC FILING

Reuters·10/06/2026 11:52:37

Please log in to view news